Pelago, a digital clinical partner to U.S. businesses and health plans for substance use management, announced $58 million in new funding that now brings total funding to $151 million, which will be used to expand offerings for payers and employers.

The additional capital will help Pelago accelerate its product roadmap, extend its continuum of care and advance clinical research efforts, the company said. 

Skip to content